BDXBecton Dickinson and Company

About Becton Dickinson and Company
Becton Dickinson and Company (NYSE:BDX) specializes in medical technology, aiming to improve medical discovery, diagnostics, and the delivery of care. With a global reach, their operations span manufacturing and selling a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Their projects often focus on innovation in patient safety, healthcare worker safety, and clinical efficiencies. Objectives include advancing the world of health by enhancing diagnostics and the administration of healthcare through simpler, more accessible, and safer methods. Becton Dickinson is committed to sustainability and addressing global healthcare challenges, working towards ensuring high-quality patient outcomes worldwide.
What is BDX known for?
Snapshot
Public US
Ownership
1897
Year founded
44532
Employees
Franklin Lakes, United States
Head office
1 of 348
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Becton Dickinson and Company
- Offering a global view in diagnosing infectious diseases, the BD Veritor™ Plus System enables rapid COVID-19 testing.
- In the realm of medicinal delivery, their array of syringes and needles prioritize patient comfort and safe medication dispensing.
- Their line of arterial blood collection systems facilitates precise measurement of blood gas parameters.
- Robust automation solutions ensure accurate specimen management and processing for laboratories, enhancing operational efficiency.
- BD's health analytics software uses real-time data to streamline the tracking of patient health and generate useful insights.
- Their groundbreaking urology and critical care products aim to improve treatment and dramatically lower healthcare-associated infections.
Becton Dickinson and Company executive team
- Mr. Thomas E. Polen Jr.President, CEO & Chairman
- Mr. Michael GarrisonExecutive VP & President of Medical Segment and BioPharma Systems Segments
- Mr. Richard E. ByrdExecutive VP & President of Interventional Segment
- Mr. Michael C. FeldExecutive VP, Chief Revenue Officer & President of Life Sciences Segmen
- Mr. Vitor RoqueInterim CFO
- Ms. Pamela L. SpiknerSenior VP, Chief Accounting Officer & Controller
- Ms. Elizabeth McCombsExecutive VP & CTO
- Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.Senior VP & Chief Scientific Officer
- Ms. Denise Russell FlemingExecutive VP of Technology & Global Services and Chief Information Officer
- Adam ReiffeVP of Investor Relations